Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma-Reference-Cited by-同舟云学术

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Published:2017-03-16 Issue:11 Volume:376 Page:1015-1026
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Bellmunt Joaquim,de Wit Ronald,Vaughn David J.,Fradet Yves,Lee Jae-Lyun,Fong Lawrence,Vogelzang Nicholas J.,Climent Miguel A.,Petrylak Daniel P.,Choueiri Toni K.,Necchi Andrea,Gerritsen Winald,Gurney Howard,Quinn David I.,Culine Stéphane,Sternberg Cora N.,Mai Yabing,Poehlein Christian H.,Perini Rodolfo F.,Bajorin Dean F.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1613683

Cited by 2751 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic effect of cancer therapy;Metabolomics of Bladder Cancer;2025

2. Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching;Clinical Genitourinary Cancer;2024-12

3. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor;Clinical Genitourinary Cancer;2024-12

4. Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors;Current Cancer Drug Targets;2024-11

5. Developing and experimental validating a B cell exhaustion-related gene signature to assess prognosis and immunotherapeutic response in bladder cancer;Gene;2024-11